Sio Gene Therapies Inc logo

SIOX - Sio Gene Therapies Inc Share Price

$2.51 -0.1  -2.0%

Last Trade - 05/03/21

Sector
Healthcare
Size
Small Cap
Market Cap £106.5m
Enterprise Value £42.2m
Revenue £n/a
Position in Universe 4682nd / 6651
Bullish
Bearish
Unlock SIOX Revenue
Momentum
Relative Strength (%)
1m -9.20%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -56.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 31 December 2020, Sio GeneTherapies Inc revenues was not reported. Net loss decreased48% to $29.1M. Lower net loss reflects Research anddevelopment (includes $8,02 decrease of 55% to $15.4M(expense), Interest expense decrease of 80% to $798K(expense), General and administrative (includes $14decrease of 19% to $11M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SIOX Revenue Unlock SIOX Revenue

Net Income

SIOX Net Income Unlock SIOX Revenue

Normalised EPS

SIOX Normalised EPS Unlock SIOX Revenue

PE Ratio Range

SIOX PE Ratio Range Unlock SIOX Revenue

Dividend Yield Range

SIOX Dividend Yield Range Unlock SIOX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SIOX EPS Forecasts Unlock SIOX Revenue
Profile Summary

Sio Gene Therapies Inc., together with its wholly owned subsidiaries, is a clinical-stage company focused on developing gene therapies for neurodegenerative diseases. The Company is developing a pipeline of product candidates for the treatment of these debilitating diseases, including Parkinson's disease, GM1 gangliosidosis and GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease). The Company’s subsidiaries include Axovant Holdings Ltd, Axovant Sciences Inc, Axovant Sciences GmbH, Axovant Sciences Amercia, Inc., Axovant Treasury Holdings, Inc., Axovant Treasury, Inc and Axovant Sciences Europe Ltd. The Company’s clinical-stage programs include AXO-Lenti-PD, AXO-AAV-GM1 and AXO-AAV-GM2 program.

Directors
Last Annual March 31st, 2020
Last Interim December 31st, 2020
No. of Shareholders: 4
No. of Employees: 38
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 58,750,611
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SIOX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SIOX
Upcoming Events for SIOX
Frequently Asked Questions for Sio Gene Therapies Inc
What is the Sio Gene Therapies Inc share price?

As of 05/03/21, shares in Sio Gene Therapies Inc are trading at $2.51, giving the company a market capitalisation of £106.5m. This share price information is delayed by 15 minutes.

How has the Sio Gene Therapies Inc share price performed this year?

Shares in Sio Gene Therapies Inc are currently trading at $2.51 and the price has moved by -17.16% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sio Gene Therapies Inc price has moved by -34.66% over the past year.

What are the analyst and broker recommendations for Sio Gene Therapies Inc?

Of the analysts with advisory recommendations for Sio Gene Therapies Inc, there are there are currently 2 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Sio Gene Therapies Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Sio Gene Therapies Inc next release its financial results?

Sio Gene Therapies Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Sio Gene Therapies Inc dividend yield?

Sio Gene Therapies Inc does not currently pay a dividend.

Does Sio Gene Therapies Inc pay a dividend?

Sio Gene Therapies Inc does not currently pay a dividend.

When does Sio Gene Therapies Inc next pay dividends?

Sio Gene Therapies Inc does not currently pay a dividend.

How do I buy Sio Gene Therapies Inc shares?

To buy shares in Sio Gene Therapies Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Sio Gene Therapies Inc?

Shares in Sio Gene Therapies Inc are currently trading at $2.51, giving the company a market capitalisation of £106.5m.

Where are Sio Gene Therapies Inc shares listed? Where are Sio Gene Therapies Inc shares listed?

Here are the trading details for Sio Gene Therapies Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: SIOX
What kind of share is Sio Gene Therapies Inc?

Based on an overall assessment of its quality, value and momentum, Sio Gene Therapies Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Sio Gene Therapies Inc share price forecast 2021?

Shares in Sio Gene Therapies Inc are currently priced at $2.51. At that level they are trading at 0.254% discount to the analyst consensus target price of 0.00.

Analysts covering Sio Gene Therapies Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.888 for the next financial year.

How can I tell whether the Sio Gene Therapies Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sio Gene Therapies Inc. Over the past six months, the relative strength of its shares against the market has been -25.28%. At the current price of $2.51, shares in Sio Gene Therapies Inc are trading at -18.61% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Sio Gene Therapies Inc PE Ratio?

We were not able to find PE ratio data for Sio Gene Therapies Inc.

Who are the key directors of Sio Gene Therapies Inc?

We were unable to find the directors for Sio Gene Therapies Inc.

Who are the major shareholders of Sio Gene Therapies Inc?

Here are the top five shareholders of Sio Gene Therapies Inc based on the size of their shareholding:

Roivant Sciences Ltd. Corporation
Percentage owned: 31.62% (18.6m shares)
Consonance Capital Management LP Hedge Fund
Percentage owned: 5.42% (3.19m shares)
Rubric Capital Management LP Investment Advisor
Percentage owned: 3.97% (2.34m shares)
Opaleye Management Inc. Hedge Fund
Percentage owned: 3.4% (2.00m shares)
Hudson Bay Capital Management LP Hedge Fund
Percentage owned: 2.72% (1.60m shares)
Similar to SIOX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.